Exhibit 99(b)

MERCK & CO., INC.
FOURTH QUARTER

		4Q '01			4Q '00			% CHG.
TOTAL SALES		$	12,558.0		$	11,467.3			10	%
TOTAL COSTS, EXPENSES, & OTHER		$	9,899.5		$	8,956.2
	Materials & Production		7,642.4			6,570.6
	Marketing & Administrative		1,555.4			1,774.1
	Research & Development		716.4			662.4
	Equity Income From Affiliates		(128.2	)		(145.5	)
	Other (Income)/Expense, Net		113.5			94.6
PRE-TAX INCOME		$	2,658.5		$	2,511.1
TAXES		$	797.6		$	746.7
TAX RATE			30.0	%		29.7	%
NET INCOME		$	1,860.9		$	1,764.4			5	%
EPS — ASSUMING DILUTION			$0.81			$0.75			8	%
AVG. # SHARES — ASSUMING DILUTION			2,301.0			2,355.8

	4Q '01		% CHG.		VOL		PX		FX
TOTAL SALES		$12,560		10%		5		6	-1
Total U.S. and Foreign Sales		5,595		4%		8		-2	-2
U.S.		3,485		0%		2		-2	0
Foreign		2,110		11%		17		-2	-4
Other Medco Sales		6,965		15%

Exhibit 99(b)

MERCK & CO., INC.
FULL YEAR

		2001			2000			% CHG.
TOTAL SALES		$	47,715.7		$	40,363.2			18	%
TOTAL COSTS, EXPENSES, & OTHER		$	37,313.1		$	30,539.1
	Materials & Production		28,976.5			22,443.5
	Marketing & Administrative		6,224.4			6,167.7
	Research & Development		2,456.4			2,343.8
	Equity Income From Affiliates		(685.9	)		(764.9	)
	Other (Income)/Expense, Net		341.7			349.0
PRE-TAX INCOME		$	10,402.6		$	9,824.1
TAXES		$	3,120.8		$	3,002.4
TAX RATE			30.0	%		30.6	%
NET INCOME		$	7,281.8		$	6,821.7			7	%
EPS — ASSUMING DILUTION			$3.14			$2.90			8	%
AVG. # SHARES — ASSUMING DILUTION			2,322.3			2,353.2

			2001		% CHG.			VOL		PX		FX
TOTAL SALES			$	47,715		18	%		14		5		-1
	Total U.S. and Foreign Sales			21,350		6	%		8		0		-2
		U.S.		13,590		5	%		4		1		0
		Foreign		7,760		6	%		14		-1		-7
	Other Medco Sales			26,365		31	%

Exhibit 99(b)

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2001

OTHER (INCOME)/EXPENSE, NET

							FULL			FULL
	4Q '01			4Q '00			YEAR 2001			YEAR 2000
INTEREST INCOME	$	(109.8	)	$	(144.2	)	$	(490.1	)	$	(470.6	)
INTEREST EXPENSE		109.5			129.3			464.7			484.4
EXCHANGE (GAINS)/LOSSES		15.1			(2.5	)		(3.5	)		(34.4	)
MINORITY INTERESTS		72.3			77.9			290.6			308.7
AMORTIZATION OF GOODWILL AND INTANGIBLES		85.3			81.0			330.1			319.1
Other, net		(58.9	)		(46.9	)		(250.1	)		(258.2	)
TOTAL	$	113.5		$	94.6		$	341.7		$	349.0

JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a “NET” basis, rounded to the nearest $5 million.

					FULL		FULL
Merial	4Q '01		4Q '00		YEAR 2001		YEAR 2000
IVOMEC, HEARTGARD, other avermectins	$	130	$	130	$	495	$	535
FRONTLINE		70		70		410		345
Biologicals		100		80		355		320
Other Animal Health		45		45		190		195
Poultry Genetics		55		50		210		215
TOTAL MERIAL SALES	$	400	$	375	$	1,660	$	1,610

					FULL		FULL
Aventis Pasteur-MSD	4Q '01		4Q '00		YEAR 2001		YEAR 2000
HEPATITIS VACCINES	$	20	$	25	$	90	$	135
VIRAL VACCINES		5		10		40		45
Other Vaccines		105		100		370		360
TOTAL AP-MSD SALES	$	130	$	135	$	500	$	540

TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (in millions)

	2001		2000		% Chg
FIRST QUARTER		138		99		39	%
SECOND QUARTER		134		98		37	%
THIRD QUARTER		128		120		7	%
FOURTH QUARTER		137		135		2	%
YEAR TO DATE		537		452		19	%

Exhibit 99(b)

MERCK & CO., INC.
PRODUCT SALES DETAIL

	4Q '01 vs. 4Q '00
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
VIOXX		-21	%	$	550		-36	%	$	365		42	%	$	185
VASOTEC / VASERETIC		-24	%		250		-69	%		20		-13	%		230
PRINIVIL / PRINZIDE		33	%		320		37	%		295		0	%		25
COZAAR / HYZAAR		-11	%		470		-42	%		155		19	%		315
MEVACOR		-4	%		120		-10	%		95		25	%		25
ZOCOR		41	%		2,055		55	%		1,500		13	%		555
AGGRASTAT		33	%		40		0	%		25		N/M			15
SINGULAIR		43	%		350		37	%		260		64	%		90
MAXALT		18	%		65		13	%		45		33	%		20
PROPECIA		11	%		50		-20	%		20		50	%		30
PROSCAR		32	%		165		46	%		95		17	%		70
PRIMAXIN		6	%		165		10	%		55		5	%		110
CANCIDAS		N/M			15		N/M			10		N/M			5
PEPCID		-90	%		25		-93	%		15		-50	%		10
FOSAMAX		49	%		470		60	%		335		29	%		135
CRIXIVAN/STOCRIN		-38	%		75		-64	%		20		-15	%		55
TIMOPTIC/TIMOPTIC XE		-31	%		45		N/M			5		-11	%		40
TRUSOPT/COSOPT		25	%		125		33	%		60		18	%		65
HEPATITIS VACCINES		-7	%		70		-14	%		60		N/M			10
VIRAL VACCINES		-22	%		90		-24	%		80		0	%		10
OTHER VACCINES		N/M			70		N/M			25		N/M			45

NOTE: Product sales rounded to the nearest $5 million.

N / M — Not Meaningful

Exhibit 99(b)

MERCK & CO., INC.
PRODUCT SALES DETAIL

	FULL YEAR 2001 OVER 2000
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
VIOXX		18	%	$	2,555		9	%	$	1,895		59	%	$	660
VASOTEC / VASERETIC		-41	%		1,050		-82	%		130		-15	%		920
PRINIVIL / PRINZIDE		17	%		1,260		21	%		1,165		-14	%		95
COZAAR / HYZAAR		11	%		1,905		3	%		795		17	%		1,110
MEVACOR		-2	%		510		0	%		425		-11	%		85
ZOCOR		26	%		6,670		38	%		4,690		6	%		1,980
AGGRASTAT		-4	%		125		-20	%		80		50	%		45
SINGULAIR		60	%		1,375		58	%		1,060		66	%		315
MAXALT		42	%		270		45	%		210		33	%		60
PROPECIA		8	%		210		11	%		105		5	%		105
PROSCAR		22	%		575		33	%		305		13	%		270
PRIMAXIN		0	%		605		3	%		185		-1	%		420
CANCIDAS		N/M			40		N/M			30		N/M			10
PEPCID		-58	%		355		-62	%		295		-20	%		60
FOSAMAX		38	%		1,760		45	%		1,275		23	%		485
CRIXIVAN/STOCRIN		-23	%		410		-19	%		170		-25	%		240
TIMOPTIC/TIMOPTIC XE		-18	%		210		-29	%		50		-14	%		160
TRUSOPT/COSOPT		16	%		425		21	%		205		13	%		220
HEPATITIS VACCINES		-1	%		340		-3	%		305		17	%		35
VIRAL VACCINES		-1	%		515		-2	%		475		14	%		40
OTHER VACCINES		N/M			170		N/M			90		N/M			80

NOTE: Product sales rounded to the nearest $5 million.

N / M — Not Meaningful